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Abstract 
EXTERNAL QUALITY-CONTROL SURVEYS OF PEPTIDE HORMONE RADIO-
IMMUNOASSAYS IN THE FEDERAL REPUBLIC OF GERMANY: THE PRESENT STATUS. 
Two types of quality-control survey (QCS) of hormone assays are performed in the 
Federal Republic of Germany. In the one survey, the participating laboratories are requested 
to determine seven or eight different hormones in two lyophilized sera that are distributed 
several times a year. Because of the lack of reference methods for peptide hormones, the 
statistical evaluation of the results indicates only whether they are "correct" or subject to 
systematic or nonsystematic errors with respect to the findings of the other participants. 
In the other survey, the participating laboratories are requested to assay only one given hormone 
in some 20 deep-frozen sera (including standards in hormone-free sera for derivation of a 
standard curve) that are distributed at relatively long intervals. The statistical analysis of the 
data derived from these QCSs allows — together with the methodological inquiry form -
detection of probable causes for discrepancies in the results. 
During recent years a system has been introduced in the Federal Republic 
of Germany (FRG) for internal and external quality control of quantitative 
clinical chemical analyses. This quality control is conducted according to the 
guidelines of the Bundesärztekammer (Medical Association of the FRG) [1 ] . 
The guidelines are based on the Calibration Act of 1969, which requires that 
i f the instruments used for the determination of volume are not officially 
calibrated, the accuracy of analytical results has to be demonstrated by means 
of continuous monitoring with the methods of statistical quality control. 
* Supported by the Bundesministerium für Forschung und Technologie. 
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TABLE I . COEFFICIENTS OF VARIATION OF THE RESULTS OF THE THIRD AND FOURTH QUALITY-CONTROL 
SURVEY FOR HORMONE DETERMINATIONS (BONN) 
Survey Compound T 3 T 4 TSH Prolactin LH FSH hGH Insulin 
3 Number of 66 71 50 32 44 41 29 28 
results 
CV(%) (Sample A) 23 18 53 28 - 38 39 42 
CV(%) (Sample B) 27 18 54 31 53 33 58 51 
4 Number of 63 68 47 31 45 40 29 33 
results 
CV(%) (Sample A) 25 24 43 42 38 34 44 49 
CV(%) (Sample B) 25 23 32 38 28 32 37 28 
Results lying beyond the double value of the median were omitted. 
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FIG. 1. Youden plot of a QCS of TSH assays with two sera. The x-axis shows the results of 
sample A, the y-axis those of sample B. The expected value lies in the middle of the 45° line. 
Deviations along the line show systematic errors, deviations away from the line show 
random errors. 
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TABLE I I . 50%, 16% AND 84% PERCENTILES (mU/litre) OF TSH DETERMINATIONS DIVIDED ACCORDING TO 
COMMERCIAL KITS USED BY THE PARTICIPANTS OF THE FOURTH SURVEY (BONN) 
Kit (No.) I 4 5 6 7 8 9 10 
Number of 
results 
9 6 7 2 10 5 3 2 
< 
ω 
I—) 
ρ , 
50% percentile 
(median) 
2.9 7.9 2.8 3.2 2.2 2.0 1.9 2.3 
< 16% percentile 1.0 1.8 1.4 - 1.4 - - -
CO 84% percentile 11.1 27.2 3.4 - 4.2 - - -
>L
E
B 50% percentile 
(median) 
16.6 27.5 22.4 13.8 16.9 12.0 13.5 13.3 
t-M 
< 
16% percentile 10.9 11.8 16.7 - 13.9 - - -
CO 84% percentile 49.6 55.8 27.2 - 29.1 - - -
ε. 
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FIG. 2. QCS of TSH assays. Mean regression of all assays (separated according to incubation 
mode} between ascribed values and measured values in the dose range between 1.8 and 26 μϋ 
TSH/ml. 
The system of external quality control for routine clinical chemical 
analyses is now well established [2] . In each quality-control survey (QCS) at 
least two specimens, differing in concentrations of the various constituents, 
are to be analysed by the participating laboratories. The results are evaluated 
on the basis of assigned values and the standard deviations, as calculated 
from the results of reference laboratories. A single result meets the require­
ments provided it lies between the limits of the assigned value plus or minus 
three times the interlaboratory standard deviation of the reference laboratories. 
The participant receives a certificate to this effect which is valid for 12 months. 
In the Federal Republic of Germany there are two institutions officially 
authorized and acknowledged by the Bundesärztekammer that carry out 
external quality surveys in the field of clinical chemistry, namely the Institut 
für Klinische Biochemie der Universität Bonn (supported by the German 
Society for Clinical Chemistry) and the Institut für Standardisierung und 
Dokumentation, Düsseldorf. 
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FIG. 3. Graphs from a QCS of TSH assays showing four typical relationships between the 
standard curves of the participating laboratories (· ) and the recovery curves ( ) . The 
abscissa is logarithmic and shows the TSH concentrations (μϋ/ml) of the participants' 
standard curves. 
fa) Laboratory-developed assay (non-kit) (cold preincubation, double-antibody separation). 
Both curves show perfect agreement. 
(b) Kit assay (equilibrium, cellulose-bound second antibody separation). Good agreement 
only in the high dose range. High blanks. 
As far as hormone assays are concerned, the legal regulations can only be 
partly met because of a number of technical difficulties. Thus, there are 
numerous techniques for the measurement of hormones in biological fluids. 
Although some of these methods may give satisfactory levels of precision, 
many of them yield unsatisfactory results, particularly with respect to 
accuracy and specificity. 
For steroid hormone assays, however, it may be possible in the not too 
distant future to find a way to carry out QCSs according to the legal guidelines. 
The true values of the concentrations can, on the one hand, be obtained by 
adding defined quantities of steroids to plasma samples from which endogenous 
steroids have been removed; on the other hand, these low molecular hormones 
can be determined by a definitive method (isotope dilution-mass fragmentography). 
Four pilot QCSs performed on this basis by the Bonn study group have proven 
the practicability of this system. 
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(c) Kit assay (equilibrium, double antibody). Different slope of standard and recovery curve 
(standards in buffer instead of in hormone-free serum). 
(d) Kit assay (mixing of tracer and first antibody before pipetting to save one pipetting step; 
second antibody separation). False high values over the whole range. 
It seems to be much more difficult to create an equivalent basis for the 
evaluation of results of QCSs for peptide hormones. At present, no possibility 
exists to determine the true concentrations of peptide hormones; as long as no 
agreement has been reached on standardized analytical methods, values obtained 
by reference laboratories cannot reasonably be used for the evaluation of the 
results. 
The efforts of the two institutions at Bonn and at Munich are directed to 
establish the conditions for an optimalization and standardization of the 
determinations of peptide hormones. Up to now, the Bonn group has included 
six peptide hormones in their QCSs which are offered about three times a year; 
the form of organization of these QCSs follows the legal rules set up for clinical 
chemical determinations. The results of each of these surveys yield information 
[ 1 ] on the extent to which the analytical values of the various laboratories are 
comparable to each other, and [2] whether there is a relation between the 
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FIG.4. QCS of TSH assays. Mean recovery of all participants in the dose range between 
1.8 and 26 μϋ TSH/ml. Each box contains the participant's number and a symbol indicating 
the method or kit used. 
differing results and the reagents used. The QCSs performed by the Munich 
group are concerned with only one compound which is determined by the 
participating laboratories in a large number of samples. In this way, detailed 
information may be obtained about the sources of errors influencing the results. 
The findings of the QCSs are demonstrated by some examples. In two 
surveys carried out by the Bonn group in 1977 in which more than 100 labora­
tories participated, the following peptide hormones were determined: TSH, 
prolactin, LH, FSH, hGH and insulin; in addition, tri-iodothyronine ( T 3 ) and 
thyroxine ( T 4 ) were analysed. Table I shows the interlaboratory imprecision — 
given as coefficients of variation - of the participants' results for each compound. 
Whereas T 3 and T 4 were determined with relatively good precision, the 
coefficients of variation for the peptide hormones were rather high. In some 
cases, an improvement from the third to the fourth survey was noticed. With LH, 
the increase in precision was probably due to the fact that the samples of the 
fourth survey were supplied together with the same standard material of this 
hormone. 
The results for each compound in each survey were analysed as a Youden 
plot, all pairs of results within the range of zero and the double value of the 
median being included. Figure 1 demonstrates this for TSH from the fourth 
survey. From Table I I it can be speculated that the scatter of the results may 
depend, at least to some extent, on the origin of the kits. Laboratories that 
used kit No. 4 measured significantly higher values than most of the other 
participants. An interpretation of this phenomenon will only be possible when 
more information becomes available. 
A second and more complex form of QCS has been carried out by the 
Endocrinological Study Group of the University Clinic in Munich. Here, 
approximately 20 serum samples are sent express in dry-ice to each participant. 
In these sera, a concealed standard curve in hormone-free serum, including a 
zero value, serves as a control to check the method and standards in use in the 
participants' laboratory. The remaining tubes contain interfering substances, 
serum from function tests, e.g. OGTT in an insulin quality control survey, 
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FIG. 5. QCS of TSH assays. 
fa J Histogram of the results for one pooled serum (17.5 μϋ TSH/ml) taken from each 
laboratory standard curve fx = mean value, CV = coefficient of variation). 
fb) Histogram of the results for the same pooled serum taken from the recovery curves. 
TRH test in TSH, an intra-assay precision control where three tubes contain the 
same serum (in the normal range), and sera below, within and above the expected 
normal range. The 20 sera are randomly numbered to keep anonymity. Al l sera 
used are human sera from volunteer blood donors. Hormone-free serum is 
obtained either from donors who have undergone suppression therapy (e.g. T 4 
dosage to suppress TSH secretion) or from donors in whom the hormone is not 
present, e.g. hGH-free serum from hypophysectomised patients. Al l participants 
are asked to assay each serum at least in duplicate, and all count-rates as well 
as the standard curve values and test serum values obtained. A comparison 
of values obtained using the participants' standard curves and the hidden 
standard curves (recovery curves) allows a thorough evaluation of the 
methodology and the pin-pointing of the probable sources of error (Fig. 2). 
From the recovery curve, the concentrations of the participants' standard 
curves can be checked, and dilution errors of differences in immunoreactivity 
of standards detected (Fig. 3). The interfering substances show the specificity 
of the participants' antisera. 
The results from completed QCSs of this type (three surveys for insulin, 
two for TSH and one each for T 3 , T 4 , hGH and Cortisol) [3—5] show that i t 
allows the causes of methodological errors to be stated with greater probability 
than does the aforementioned type using only two sera (Figs 4 and 5). The 
90 BREUER et al. 
results to date show that the quality of results is far less dependent on the 
quality of component reagents (standards, antiserum and tracer) used — whether 
in kits or otherwise obtained — than on the methodology, such as incubation 
time, temperature, extraction and separation procedures. The disadvantage 
of this type of QCS lies in the large number of samples sent to each laboratory 
and the relatively long period needed for the data-processing and feed-back of 
information, making it impossible to carry out frequently. A compromise 
might be a combination of both methods in which the control sera for the 
"2-sera" QCS would be determined first in a "20-sera" QCS, thus allowing a 
better-assigned value to be put on each sample. 
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